Sana adds hypoimmunogenic stem cell tech from Harvard to its tool kit

Building out its portfolio of cell and gene therapy tools, Sana licensed technology from Harvard University comprising methods to create stem cells that avoid triggering immune rejection when transplanted.

The hypoimmunogenic stem cells are derived

Read the full 346 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE